Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs

Centessa is one of several companies developing a new class of drugs to treat narcolepsy. The item is purely descriptive with no clinical-stage, timeline, or commercial details, suggesting limited near-term market impact.

Analysis

Centessa is one of several companies developing a new class of drugs to treat narcolepsy. The item is purely descriptive with no clinical-stage, timeline, or commercial details, suggesting limited near-term market impact.